TRNR Publishes Q&A With Ergatta Co-Founder and CEO Tom Aulet on the Business Behind Its Newest Brand
AUSTIN, TX / ACCESS Newswire / June 10, 2026 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of...
Pharmaceutical
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders...
SimiTree Appoints Drew McCartney as Executive Vice President of Behavioral Health, Signaling Deep and Lasting Commitment to the Sector
Veteran healthcare executive joins SimiTree to drive growth, innovation, and operational excellence for behavioral health providers nationwide HAMDEN, CT /...
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster...
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the...
Many Cancer Patients Leave Treatment Options on the Table – You Don’t Have To
Thousands of cancer patients have untapped treatment options in their genomic data. Now they can find them. Available in 12...
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Additional Orange Book Listed Patent Secured and Composition of Matter Patent is Eligible for 5-Year ExtensionCAMBRIDGE, Mass., June 10, 2026...
Zomedica Announces “Fourth Friday at Four” Webinar on June 26, 2026: The Five Pillars of Zomedica – Framework for Clinical Value and Shareholder Returns
June session to present the strategic framework behind every Zomedica product and investment decision, connecting pet care outcomes, veterinary practice...
Who Does the Best Blepharoplasty in Florida?
The Best Blepharoplasty in Florida is Done by Dr. Sessa, at Sarasota Surgical Arts SARASOTA, FL / ACCESS Newswire /...
RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer
Approval follows FDA inspection of RadioMedix’s manufacturing site with no Form 483 observations, underscoring the Company’s radiopharmaceutical manufacturing and quality...
Parexel to Showcase Seven Research Posters and Debut New Hematology Playbook at the European Hematology Association Congress 2026
Five in-person poster presentations and two virtual posters highlight Parexel’s thought leadership in real-world evidence, comparative outcomes and regulatory insights...
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company...
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo’s lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in LondonSOLANA BEACH, Calif., June...
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
FDA grants Orphan Drug Designation (ODD) to Tris Pharma’s TRN-257 for the treatment of idiopathic hypersomnia, based on the plausible...
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance...
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid...
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure...
Ligand Announces 2026 Investor Day in New York City
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an...
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across GermanyNEUMÜNSTER,...
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD communityNDS is...